目的：评价依折麦布联合辛伐他汀对冠心病高脂血症患者的疗效及安全性。方法入选2011年6月至2013年8月在北京军区总医院干一科住院的冠心病高脂血症患者60例。随机分为对照组和治疗组，每组30例。检测患者治疗前后总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、三酰甘油（TG）水平，观察并记录不良反应。结果在对照组中，与治疗前比较，治疗后TC、TG和LDL-C均降低，差异具有统计学意义（P均＜0.05）。在治疗组中，与治疗前比较，治疗后TC、TG和LDL-C均降低，差异具有统计学意义（P均＜0.05）。与对照组治疗后比较，治疗组TC[（4.10±1.24）mmol/L]、TG[（1.64±0.75）mmol/L]和LDL-C[（2.33±0.75）mmol/L]均降低，差异具有统计学意义（P均＜0.05）。药物降脂治疗后，对照组LDL-C的达标率为46.7%，治疗组为76.7%，差异有统计学意义（P＜0.05）。结论依折麦布联合辛伐他汀可达到强化降脂的效果，疗效优于单独应用辛伐他汀，且不良反应较少。%Objective To review the efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia. Methods The patients (n=60) were chosen from Jun. 2011 to Aug. 2013, and then randomly divided into control group and treatment group (each n=30). The levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and triglyceride (TG) were detected and adverse reactions were observed and recorded. Results The levels of TC, TG and LDL-C decreased in control group and treatment group (all P<0.05) after treatment. Compared with control group after treatment, TC [(4.10±1.24) mmol/L], TG [(1.64±0.75) mmol/L] and LDL-C [(2.33±0.75) mmol/L] decreased in treatment group (all P<0.05). After treatment, control rate of LDL-C was 46.7%in control group and 76.7%in treatment group (P<0.05). Conclusion Ezetimibe combining simvastatin can improve lipid-lowering efficacy, and the curative effect is superior to single simvastatin with less adverse reactions.
展开▼
